Complex study delays BMS’ decision on Galecto takeover
2016 will not be the year when Denmark’s Galecto learns whether or not Bristol-Myers Squibb will buy the biotech in a multi-million-dollar deal. CEO Hans Schambye has a good gut feeling, however, nothing is set in stone in the world of biotech.
BY LONNI LYNGE
It turns out this will not be the year when Denmark-based Galecto Biotech finds out if it will become American-owned or not. That much is clear after the basis for pharma group Bristol-Myers Squibbs’ decision on a takeover of the partner has been delayed.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Galecto signs massive deal with BMS
For abonnenter
Novo sells asset to Bristol-Myers Squibb
For abonnenter
